Treatment of Adynamic Bone Disorder With Parathyroid Hormone in Chronic Kidney Disease

Recruiting now · Phase 4

Conditions studied: Adynamic Bone Disease, Chronic Kidney Diseases, Cardiac Disease, Chronic Kidney Disease-Mineral and Bone Disorder

In brief

This study is a 1:1 randomized controlled trial with an intervention for 18 months and a follow up period of 12 months. The purpose of the study is to assess the safety and efficacy of recombinant human parathyroid hormone for treatment of adynamic bone disorder in patients with chronic kidney disease.

Key facts

Study ID: NCT04522622
Run by: Ditte Hansen
People needed: 48
Starts: 2021-12-15
Expected to finish: 2027-09-01
Last updated by the study team: 2024-04-23

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Age ≥18 years
CKD stage 4-5D (eGFR ≤29 ml/min) according to Kidney Disease Improving Global Outcomes(KDIGO) definition
DXA scan with a T-score at the total hip, femoral neck or lumbar spine (L1-4) ≤-2 (or Z-score ≤-2) in a minimum of 2 vertebraes (for patients with active oral prednisolone treatment ≥ 5 mg/day for minimum 3 months the T-score or Z-score limit i < -1) and/or former fragility fracture (vertebral, hip, for- or upper arm, ankle) assessed with VFA or x-ray of the columna
Patients with expected adynamic bone disorder, based on BSAP≤21 µg/l or biopsy-verified low bone turnover

You may not qualify if…

Hypercalcemia defined as sustained ionized calcium >1.35 mmol/l
Previous fracture withon the last 6 months *Patients may be rescreened after the 6 months
Previous calciphylaxis
Thyroid disturbances not adequately treated based on the opinion by the clinician *Patients may be rescreened after treatment optimization
Treatment with digoxin
Paget's disease or other metabolic bone disorders
Antiresorptive or bone anabolic medication during the last 24 months (for bisphosphonates it is only during the last 12 months)
Former or present malignant disease (except skin basal or planocellular carcinoma)
Previous external beam or implant radiation therapy to the skeleton
Patients who have undergone a kidney transplantation within the last 12 months
25 hydroxyvitamin D2 and D3 <50 nmol/l *Patients may be rescreened after correction
Inability to administer teriparatide
Reduced liver function *Alanine Aminotransferase (ALAT) >3x upper limit of normal or bilirubin > 2x upper limit of normal
Pregnancy, lactation or fertile women (post-menopausal females are not considered fertile) not using safe anticonception (the following contraceptive methods are considered appropriate: Intrauterine device (IUD) or hormonal anticontraceptive (oral contraceptives, implant, transdermal patches, vaginal ring or depot injection)).
Hypersensitivity to the active substance in teriparatide or to any of the excipients or content
Inability to provide informed consent
Medical conditions or treatments that may interfere with assessments of the outcomes of the trial
Drug or alcohol abuse
Unable to participate in a clinical study based on the judgement by the local investigator
For those participating in the bone biopsy procedure: 1) Hypersensitivity to any of the tetracyclines or to any of the excipients or content, 2) Treatment with anticoagulants (vitamin K antagonists, Non-vitamin K Antagonist Oral Anticoagulants (NOAC), unfractionated or low-molecular heparin or antiplatelet agents that, due to clinical indication can't be paused, 3) Disturbances in thrombosis and/or haemostasis
For those participating in pulse wave measurements: 1) Atrial fibrillation, 2) Aorta stenosis

Where it is running

Herlev and Gentofte Hospital, Herlev Hospital — Herlev, Denmark (enrolling)
Aalborg University Hospital — Aalborg, Denmark
Steno Diabetes Center Copenhagen — Gentofte Municipality, Denmark
Odense University Hospital — Odense, Denmark

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.